APA

Rep M. H., van Oosten B. W., Roos M. T., Adèr H. J., Polman C. H. & van Lier R. A. (19970624). Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. : The Journal of clinical investigation.

Chicago

Rep M H, van Oosten B W, Roos M T, Adèr H J, Polman C H and van Lier R A. 19970624. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. : The Journal of clinical investigation.

Harvard

Rep M. H., van Oosten B. W., Roos M. T., Adèr H. J., Polman C. H. and van Lier R. A. (19970624). Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. : The Journal of clinical investigation.

MLA

Rep M H, van Oosten B W, Roos M T, Adèr H J, Polman C H and van Lier R A. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. : The Journal of clinical investigation. 19970624.